Rigel Pharmaceuticals

Small molecule therapeutics for autoimmune & inflammatory diseases and cancer

Rigel (NASDAQ: RIGL) is focused on discovery and development of therapeutics against novel targets implicated in autoimmune diseases, inflammatory diseases, and cancer. Rigel completed its IPO in 2000.

Status
IPO in 2000 (NASDAQ: RIGL)
Year of Investment
1997
Strategy
Life Sciences
Location
South San Francisco, California
Frazier Team
Social Media